Philippe Camus, M.D.

Dijon, France

Back

The Drug-Induced Respiratory Disease Website

CAR T-cell therapy

I - Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)

I.a

Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
I.f

Tachycardia
I.g

QTc prolongation
I.l

Cardiac- cardiorespiratory/pulmonary arrest

II - Myocardial dysfunction - Heart failure

II.a

Left ventricular dysfunction/failure
II.c

Heart failure (biventricular, congestive)
II.d

Cardiovascular collapse - Cardiogenic shock - Hypotension
II.e

Acute respiratory or cardiopulmonary failure

III - Myocardial ischemia - Coronary artery disease

III.c

Coronary vasospasm - Vasospastic angina
III.g

ST segment changes

VI - Cardiomyopathy

VI.a

Cardiomyopathy (acute, subacute, chronic)

VII - Cardiotoxicity

VII.a

‘Cardiotoxicity’

X - Pulmonary edema

X.b

Pulmonary edema, noncardiogenic (NCPE)
X.c

Interstitial pulmonary edema

XII - Pericardial involvement

XII.b

Pericardial effusion (w/wo tamponade)

XIII - Thrombosis - Embolism

XIII.a

Pulmonary embolism - Venous thrombosis/thrombo-embolism

XIV - Pleural involvement

XIV.a

Pleural effusion (uni or bilateral) (can accompany ILD induced by the drug)

XVI - Hemorrhage - Bleeding - Hematoma(s)

XVI.i

Hemoptysis

XXII - Acute respiratory/cardiorespiratory failure

XXII.b

Acute lung injury - ARDS

XXIV - Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.k

Pulmonary infiltrates

XXXVI - Autoimmune syndromes - Systemic reactions or conditions

XXXVI.y

Cytokine release syndrome